Business divisions of large foreign pharmaceutical companies such as Pfizer and MSD are actively in progress.

Pfizer separated the patent-expired drug business unit into Pfizer Upjohn last year, and MSD is working to spin off the women's health, patent-expired drug, and biosimilar business divisions into a new corporation called Organon & Co. with the aim of the first half of next year.

The division of the division itself has a good purpose. By becoming an independent incorporation, it can be specialized in specialized fields, and the management efficiency of the company is increased.

Regardless of the will of some employees, their company name changes. The affiliation will